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INTRODUCTION 
 Oral malignancy is the sixth most common form of malignancy 
in India and it constitutes a significant part of our regular surgical work. 
 There has been an increase in incidence in oral cancer and this is 
attributed to the increased consumption of tobacco, alcohol and other 
carcinogenic products. 
 Although there is significant improvement in chemotherapy, 
radiotherapy and surgical technique, the disease is challenging as most 
patients present with advanced stage. 
 Hence an attempt to study the etiopathogenesis and outcome of 
treatment modalities of oral malignancies by a prospective and 
retrospective study in the Department of Surgery, Coimbatore Medical 
College Hospital is done. 
AIMS OF THE STUDY 
 To study the protocol and efficiency of multimodality 
management of oral cancers in our hospital. 
 Comparison of various modalities of treatment and their 
efficiency.  
 To study the stage of presentation and study of factors modifying 
the outcome. 
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REVIEW OF LITERATURE 
SURGICAL ANATOMY OF THE ORAL CAVITY AND 
PHYSIOLOGY 
 The oral cavity extends from the vermillion border of the lip to 
the hard palate/soft palate junction superiorly, to circumvallate papillae 
inferiorly and to the anterior tonsillar pillars laterally. The slit like 
space between the lips and cheeks and teeth/gingivae is the vestibule of 
the mouth. The space inside the teeth and gums is the oral cavity 
proper. The floor is the mylohyoid muscle and the roof is the hard 
palate. (Fig 1 & 2) 
It is divided into seven subsites 
♦ Lips 
♦ Alveolar ridges – upper and lower alveolus  
♦ Oral tongue – anterior two thirds limited by circumvallate 
papillae 
♦ Retromolar trigone – which overlies the ascending ramus of the 
mandible behind the last molar tooth  
♦ Floor of mouth 
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♦ Buccal mucosa – lines the cheek, inner aspect of lip which 
includes upper and lower buccoalveolar gutters 
♦ Hard palate 
Cheek and Lips 
 The substance of lips and cheek consists of facial muscle and fat. 
The parotid duct opens on the inner surface of the cheek opposite to the 
crown of the upper second molar tooth. Except the teeth, the entire 
vestibule is lined by mucous membrane. 
 The lips are fleshy folds, lined externally by skin and internally 
by mucous membrane. Each lip is composed of (a) skin (b) the 
orbicularis oris muscle (c) the submucosa containing mucous labial 
glands and blood vessels and (d) mucous membrane. 
 The cheeks are fleshy flaps, forming a large part of each side of 
the face. Each cheek is composed of (a) skin (b) superficial fascia 
containing some facial muscles, the parotid duct, mucous glands, 
vessels and nerves (c) the buccinator covered by bucopharyngeal fascia 
pierced by the parotid duct (d) submucosa with mucous buccal glands 
and (e) mucous membrane. 
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Gums 
 Gums (Gingivae) are the soft tissues which envelop the alveolar 
processes of the upper and lower jaws and surrounding the necks of the 
teeth. They are composed of dense fibrous tissue covered by stratified 
squamous epithelium. 
Hard Palate 
 The anterior two third is formed by the palatine processes of the 
maxillae, and its posterior one third by the horizontal plates of the 
palatine bones. 
Tongue 
 The tongue is essentially a mass of muscle covered by mucous 
membrane with midline, sulcus separating the two muscular halves. 
The main bulk is made up of Genioglossus muscle with some 
longitudinal and transverse intrinsic muscle fibres. Two sets of muscles 
extrinsic, intrinsic are present. The tongue practically fills the oral 
cavity proper except in its posterior portion. The posterior part of the 
tongue is connected with hyoid bone by Hyoglossi,  Genioglossi 
muscles and the Hyoglossal membrane. The inferior surface is 
connected with the mandible by the mucous membrane, which is 
reflected over the floor of mouth to the lingual surface of the gum. 
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There are projections of the corium over the anterior two third of the 
dorsum of the tongue called papillae. The various types of papillae are 
circumvallate, fungiform and filiform papillae. 
Lymphatic Drainage 
 Lymphatic drainage is mainly to the submental, submandibular 
lymphnodes in the suprahyoid region. It also drains into upper deep 
cervical lymphnodes especially the jugulo omohyoid. 
 The lymph from the lower lip, the anterior part of the alveolus, 
anterior part of the floor of the mouth and anterior third of tongue drain 
into the submental lymphnodes. 
 The remaining part of the oral cavity and middle third of the 
tongue drains into submandibular group and the upper deep cervical 
and to some extent into the submental lymphnodes. 
 The tip of the tongue drains bilaterally to the submental 
lymphnodes. The rest of the anterior two thirds drain unilaterally 
through the floor of the mouth into the submandibular nodes. There is 
some overlap across the midline. The posterior one third drains 
bilaterally into the jugulo omohyoid nodes. It is noted that the lymph 
from the tongue ultimately reaches the jugulo omohyoid nodes.  
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The cervical nodes are described under various levels. (Fig. 3) 
Level I   : Includes nodes within the submental and submandibular 
 triangle. 
 Ia : Nodes in the submental triangle bounded by the anterior 
 bellies of digastric and deep by the mylohyoid. 
 Ib : Nodes in the submandibular triangle bounded by the anterior 
 and posterior bellies of digastric and the body of the 
 mandible. 
Level II : Includes nodes extending from the subdigastric area to the 
 carotid bifurcation and nodes surrounding the spinal 
 accessory nerve from jugular foramen to posterior border 
 of sternocleidomastoid muscle. 
 IIa : Nodes in the region anterior to the spinal accessory nerve. 
 IIb : Nodes in the region posterior to the spinal accessory nerve. 
Level III : Includes nodes principally along the jugular veins between 
 the carotid and its bifurcation, posterior border of 
 sternocleidomastoid muscle and omohyoid muscle. 
Level IV : Includes nodes below omohyoid muscle above the level of 
 clavicle between carotid vessels anteriorly and mylohyoid 
 muscle posteriorly. 
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Level V : Includes nodes in the posterior cervical triangle bounded by 
 the posterior border of the sternocleidomastoid, the 
 clavicle and the anterior border of the trapezius. 
Level VI : Includes nodes in the anterior triangle of necks bounded by 
 the anterior borders of the sternocleidomastoid extending 
 from the hyoid to the suprasternal notch.  
Blood supply of the oral cavity 
 All the parts of the oral cavity are supplied by the three branches 
of the external carotid artery.   
 The facial artery, a branch of external carotid artery supplies the 
cheek. The lingual artery, a branch of external carotid artery supplies 
the tongue. 
 Blood supply of the palate is from the greater palatine artery, a 
branch of maxillary artery which emerges from the greater palatine 
foramen and passes around the palate.  
Nerve supply of the oral cavity 
 Sensory supply to the mucous membrane of the cheek comes 
from the trigeminal nerve above by maxillary division and below by the 
mandibular division. The mucous membrane and the muscles of the 
tongue have entirely separate nerve supply. 
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 The anterior two thirds of the tongue is supplied by the lingual 
nerve whose trigeminal component mediates the common sensibility 
and whose chordatympani component mediates taste.  
 All the muscles of tongue, intrinsic and extrinsic are supplied by 
the hypoglossal nerve (except the palatoglossus which is supplied by 
pharyngeal plexus). 
PHYSIOLOGY  
1. Mastication  
 As the seat of the dental apparatus it serves to masticate the food 
and prepare it for digestion. Mastication is performed not by the 
isolated action of particular teeth or a particular jaw but by the 
combined activity and integration of the component parts as one unit. 
2. Speech 
 With the pharynx it forms the resonator for speech. 
3. Respiration 
 It also assists in respiration. However this is abnormally 
accentuated in mouth breathing. 
4. Taste 
 This harbours the organs of taste. 
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5. Absorption 
 Absorption through the mucous membrane is very rapid, its non 
corneated  epithelium being much more permeable than the epithelium 
of the skin. This fact is utilized in the topical administration for 
systemic action of drugs in the oral cavity, particularly in the region of 
the floor of the mouth and under the tongue.  
 
ETIOLOGY 
 Oral cancer represents a multiplicity of diseases. 
Tobacco 
 The relation between tobacco exposure and disease development 
has been clearly demonstrated. A clear dose response relationship has 
been identified with greater risk being directly proportional to intensity 
and duration of exposure. Users of smokeless tobacco have a four times 
increased risk of oral cavity carcinoma.4,5 
Smoking 
 The risk of malignancy is 6 times than that of nonsmokers. The 
risk increases with the number of years of smoking and number of 
cigarettes smoked per day5. 
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Betel nut and Tobacco chewing 
 Chewing dried and cured tobacco with betel nuts and lime is 
highly irritant to oral mucosa. 
Alcohol 
 Alcohol is another strong independent risk factor for oral cancer 
with multiplicative effect from combined exposure with tobacco. 
Indirectly vitamin deficiency and poor detoxifying capability due to 
alcohol induced liver dysfunction may promote carcinogenesis. 
Diet and Nutrition 
 The PlummerVinson syndrome has been associated with 
increased risk of oral malignancy. Recent studies suggest Vitamin A, C 
and carotenoids may be protective against epithelial cancers. High 
dietary consumption of fruits and vegetables has been found to provide 
protective effect4. 
Genetic 
 The over expression of p53 gene in the cancer of oral cavity has 
been correlated with smoking and drinking. The p53 gene may be used 
in future as a potential tumour marker and may help in identifying 
patients who are at risk for cancer development20. 
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Viral 
 Another possible etiologic agent for carcinogenesis is Human 
Papilloma Virus (HPV) an epitheliotropic DNA virus. HPV 16 and 18 
are implicated in 15% to 20% of oral cancers3. 
AIDS 
 Squamous cell carcinoma of upper aerodigestive tract appears to 
be common and aggressive in patients with AIDS as in other 
immunodeficiency states. Oral and pharyngeal manifestations of 
Kaposi sarcoma are common in HIV positive patients.  
Solar exposure 
 Exposure to sunlight has been implicated in the carcinoma of lip 
in susceptible population.  
Dentition 
 Poor dentition may be associated with cancer of oral cavity. 
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PREMALIGNANT LESIONS 
Lesions considered to carry a definite risk of malignant change4  
 Leucoplakia 
 Erythroplakia 
 Chronic hyperplastic candidiasis  
Conditions that are not themselves premalignant but which are 
associated with a higher than normal incidence of oral cancer4 
 Oral submucous fibrosis 
 Syphilitic glossitis  
 Sideropenic dysphagia 
Oral conditions about which there is still some doubt as to whether 
their association with oral cancer is causal or casual4  
 Oral lichen planus 
 Discoid lupus erythematosus 
 Dyskeratosis congenita 
 
Leukoplakia 
 WHO has defined leukoplakia as ‘any white patch or plaque that 
cannot be characterized clinically or pathologically as any other 
disease’. Oral leukoplakia is the most precancerous lesion of the oral 
cavity. 
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Erythroplakia 
 Erythroplakia is defined as ‘any lesion of the oral mucosa that 
presents as bright red velvety plaques that cannot be characterized 
clinically or pathologically as any other recognisable condition’. The 
incidence of malignant change in erythroplakias is 17 – fold higher than 
in leucoplakia.  
Chronic hyperplastic candidiasis  
 In this, dense chalky plaques of keratin are formed. There may 
be an immunological defect that allows the Candida albicans to invade 
the epithelium and may render the patient susceptible to malignant 
change. 
Oral submucous fibrosis 
 Oral submucous fibrosis is a progressive disease in which fibrous 
bands form beneath the oral mucosa. 
Syphilitic glossitis 
 The syphilitic infection produces an interstitial glossitis with an 
endarteritis which results in atrophy of the overlying epithelium. 
Sideropenic dysphagia 
 The sideropenic dysphagia leads to epithelial atrophy, which in 
itself is excessively vulnerable to carcinogenic irritants. 
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Oral lichenplanus 
 In erosive or atrophic lichen planus, there is a risk of malignant 
transformation. 
Discoid lupus erythematosus 
 This consists of circumscribed, elevated, white patches 
surrounded by a telangiectatic halo. 
Dyskeratosis congenita 
 This syndrome is characterized by reticular atrophy of the skin 
with pigmentation, nail dystrophy and oral leukoplakia. 
 
 
 
 
 
 
 
 
 
 
 
 15
PATHOLOGY 
MACROSCOPIC APPEARANCE 
 Oral cancers generally refer to squamous cell carcinoma of oral 
mucosal origin. More than 90% of cancers of oral cavity are squamous 
cell carcinomas. Squamous cell carcinomas are described as either 
exophytic or ulcerative or a mixture of both ie, ulceroproliferative. 
1. Proliferative type 
 The exophytic type is less common and carries a better 
prognosis. This is a soft fleshy mass has more superficial involvement 
and deep infiltration of mucosal tissues occurs in advanced stages. 
2. Superficial plaque type 
 Finely granular shallow ulceration that creeps slowly over large 
areas of mucosa with no invasive tendency. This occurs in patients with 
wide intraoral pigmentation or melanoplakia. 
3. Ulcerative Type 
 This is seen as an ulcer with heaped up edges and bleeds easily. 
This excavation is hard and infiltrates the surrounding structures and 
usually has a high histological grade. 
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HISTOPATHOLOGY 
Squamous cell carcinoma (Fig. 4) 
 Columns of epithelial cells infiltrate the dermis and in sections, it 
appears as though it got separated from the rest of the growth. In the 
centre of these masses, the same process of keratinisation goes on as 
occurs formally on the surface. The cells become converted into 
structures, hyaline masses of keratin which stain brightly with eosin 
and are identical with horny material on the surface of the skin. Hence 
this is called Epidermoid carcinoma. These hyaline masses are often 
called as “Cell nests” or “Epithelial pearls”3. 
 The outer cells of the pearls are often arranged in a concentric 
manner. The unchanged cells show the prickle cell appearance, 
characteristic of epidermoid carcinoma. The presence of epithelial 
pearls is a sign of differentiation and of good prognostic value. In 
secondary nodes the appearances may be similar to those in the primary 
tumour. 
Basaloid squamous cell carcinoma 
 It is an aggressive form of squamous cell carcinoma. 
Verrucous carcinoma (Fig. 5) 
 It is an uncommon variant of squamous cell carcinoma and 
represents less than 5% of all oral cancers. It is considered as a low 
grade malignancy and metastasizes rarely. Radiation induced anaplastic 
transformation has been reported in multiple studies. This is the only 
malignancy where local excision is sufficient. 
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METHODS OF SPREAD 
LOCAL SPREAD 
 It extends to the adjacent structures by direct infiltration. It can 
extend into the retromolar area, alveolus and may infiltrate and ulcerate 
the skin. 
LYMPHATIC SPREAD 
 The first group of nodes to be affected from the buccal mucosa 
carcinoma is the submandibular node. From these nodes, when the 
disease advances, spread occurs to the upper deep cervical nodes. Very 
rarely spread occurs to the nodes in the posterior triangle. This occurs 
only in very advanced stage of the disease. The oral cancer as a whole 
is confined to the organ of origin for a long time, before it disseminates 
to the lymphnodes which drain the part1. 
HAEMATOGENOUS SPREAD 
 This may occur from invasion of the blood vessels by the 
primary tumour or lymphnodal secondaries, to the distant organs. 
 The most common site of distant metastasis is the lung followed 
by liver and bone.  
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CLINICAL FEATURES AND DIAGNOSIS 
TONGUE (Fig. 6 & 7) 
 The majority of tongue cancers occur in the middle third of the 
lateral margins extending in the course of disease on to the ventral 
aspect and floor of mouth. Often the growth is exophytic with areas of 
ulceration. It may occur as an ulcer in the depths of a fissure or as an 
area of superficial ulceration with infiltration into the underlying 
muscle. Excessive salivation, Foetor oris, Ankyloglossia are the other 
symptoms. Pain is a late symptom due to involvement of lingual nerve. 
Lymph node metastasis is common and present as lump in the neck.8 
THE FLOOR OF THE MOUTH (Fig. 8) 
 The lesion usually starts as an indurated mass which soon 
ulcerates. At an early stage the tongue and lingual aspect of the 
mandible becomes involved. This leads to slurring of speech. Advanced 
lesions present with pain, bleeding and foul breath. Spread to 
submandibular and jugulodigastric nodes occur and may be bilateral. 
THE GINGIVA AND ALVEOLAR RIDGE (Fig. 9) 
 The patient comes with swelling on the gum, bleeding on 
mastication, ulceration around the teeth,  illfitting dentures, history of 
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tooth extraction and subsequent failure of the socket to heal and trismus 
in advanced stage. 
THE BUCCAL MUCOSA (Fig. 10) 
 Patient notices an ulcer or  swelling at the angle of the mouth or 
inside the cheek. May or may not have foul smelling discharge. May 
present with trismus with deep infiltration into the buccinator muscle. 
The overlying skin of the cheek becomes involved and finally ulcerates 
forming an orocutaneous fistula (Fig. 11). Few come for secondary 
lymphnode enlargement. 
 Squamous cell carcinoma mostly arises at the commisure or 
along the occlusal plane. 
 Verrucous carcinoma occurs as a proliferative exophytic lesion 
with minimal deep invasion and induration. The lesion presents as a 
soft white velvety area mimicking benign hyperplasia. Lymphnode 
metastasis is rare.  
THE HARD PALATE AND MAXILLARY ALVEOLAR RIDGE 
 Cancer of palate is common where reverse smoking is practiced. 
They present as sessile swelling which ulcerate late. Late symptoms are 
nasal obstruction, discharge or bleeding and dental symptoms such as 
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painful or loose teeth, ill fitting dentures, oroantral fistula or failure of 
an extraction socket to heal. 
LIP 
 Lower lip is most commonly affected. The lesion is situated 
usually to one side of the midline. It can present as nodule or ulcer with 
bleeding and offensive discharge or neck lump. 
RETROMOLAR TRIGONE 
 It can present as pain referred to external auditory canal or 
preauricular area or trismus.  
 
INVESTIGATIONS 
1. BIOPSY 
 Biopsy plays a main diagnostic tool in oral malignancies. It is 
always done on any doubtful or obvious malignant lesions of the oral 
cavity. Positive biopsy confirms malignancy but a negative malignancy 
does not exclude malignancy7. 
Procedure 
 It is preferable to do biopsy under GA, so that a good bit of 
normal tissue at the margin of growth can easily be taken without 
discomfort to the patient. Some authors feel that injection of 
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local anaesthetic causes dissemination of malignant cells. To 
obviate risk of dissemination Lignocaine jelly was used 
topically. 
 Biopsy is taken with sharp instrument. An allis forceps is put 
over margin of the growth and a eleven blade knife is used to cut 
around it and remove a bit of adjoining normal mucosa along 
with margin of the lesion. 
 Area selected for biopsy must be free from necrotic tissue. 
 Specimen must be immediately immersed in 3% formalin 
solution. 
 
2. FINE NEEDLE ASPIRATION CYTOLOGY 
 FNAC of the neck nodes after giving antibiotics 
Role of FNAC is 
 Staging the disease. 
 Establishing the diagnosis of any recurrent  disease in the 
lymphnode or as a nodule. 
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3. RADIOLOGY 
  X–ray mandible defines mandibular invasion. An 
orthopantomogram (Fig. 12) gives better delineation of any bone  
involvement. 
 
4. CT SCAN 
 Value of CT in intraoral tumours is more limited for evaluation 
of antral tumours and pterygoid regions. CT scan can be used to predict 
perineural and vascular invasion by oral malignancy. CT brings out 
some of the lymphnodes not palpable clinically. 
5. Routine hemogram, chest radiograph, ultra sound abdomen and liver 
function test 
6. Blood VDRL 
7. Dental consultation 
8. Laryngoscopy, Bronchoscopy and Esophagoscopy for more accurate 
assessment in certain cases and for presence of another primary. 
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CLINICAL STAGING AND HISTOLOGICAL GRADING 
TNM Staging for Oral Cavity Carcinoma5 
Primary tumour 
TX  Unable to assess primary tumour 
T0  No evidence of primary tumour 
Tis  Carcinoma in situ 
T1  Tumour is < 2 cm in greatest dimension 
T2  Tumour > 2 cm and < 4 cm in greatest dimension 
T3  Tumour > 4 cm in greatest dimension 
T4 (lip) Primary tumour invading cortical bone, inferior alveolar  
  nerve,  floor of mouth,  or skin of face (e.g., nose or chin) 
T4a (oral) Tumour invades adjacent structures (e.g., cortical bone,  
  into deep tongue musculature, maxillary sinus) or skin of face 
T4b (oral) Tumour invades masticator space, pterygoid plates, or  
  skull base and/or encases the internal carotid artery 
 
Regional lymphadenopathy 
NX  Unable to assess regional lymph nodes 
N0  No evidence of regional metastasis 
N1  Metastasis in a single ipsilateral lymph node, 3 cm or less 
  in greatest dimension 
N2a  Metastasis in a single ipsilateral lymph node, > 3cm and < 6 cm 
N2b  Metastasis in multiple ipsilateral lymph nodes, all nodes < 6 cm 
N2c  Metastasis in bilateral or contralateral lymph nodes, all nodes < 6 cm 
N3  Metastasis in a lymph node > 6 cm in greatest dimension 
Distant metastases 
MX  Unable to assess for distant metastases 
M0  No distant metastases 
M1  Distant metastases 
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STAGE GROUPING 
STAGE  I  : T1N0M0 
STAGE  II   : T2N0M0 
STAGE III   : T3N0M0 
    T1T2T3 with N1M0 
STAGE IV  : T4 any N, M 
    N2 any T, M 
    M1 any T, N 
HISTOLOGICAL GRADING 
GRADE I  - well differentiated  
GRADE II – moderately differentiated 
GRADE III – poorly differentiated 
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TREATMENT MODALITIES 
 Treating the patient with oral malignancy is complex. Each 
specific site of disease, the extent of disease and the pathologic findings 
dictate the appropriate surgical procedure, radiation fields, dose and 
fractionation and indications for chemotherapy.  
 105 patients with T1 – 2 N0 – 1 carcinoma were studied after  
treating adequately by radical surgical resection and concluded that 
early cancer is adequately treated by surgery alone, provided the 
resection margins are tumour free. (Markus et al., 2000).38 
 Early stage (I and II) oral carcinoma can be treated with surgery 
or radiation. Five year survival rates are similar for both modalities6. 
 In advanced stage (III and IV), a combination of surgery and 
radiation therapy provides the best survival rate although this increases 
complication and morbidity9. 
 Induction chemotherapy followed by surgery with or without 
postoperative radiotherapy is optimum multidisciplinary therapy. 
(Watne, A.L., 2000)39 
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Ca oral cavity : Acc to NCCN – National Comprehensive Cancer 
Network guidelines34. 
T1 – 2, N0 Excision of primary tumour ± unilateral or bilateral 
selective neck dissection OR Ext. beam RT  ± 
Brachytherapy 
T3, N0   Excision of primary and reconstruction and unilateral 
or bilateral selective neck dissection followed by RT 
or CT / RT 
T1 – 3, N1-3 
T4, Any N 
Surgery –  Excision  of  primary,  Ipsilateral  or  
bilateral  neck dissection Reconstruction as   indicated  
followed    by    RT  or CT / RT   
Unresectable   CT + RT 
 
PRINCIPLES OF SURGERY 
 Available surgical procedures for primary include wide excision, 
complete oral resection, complete oral resection with Hemimandibulectomy, 
Maxillectomy and Hemiglossectomy12,18. 
 Margins of surgical resection vary from site to site. Positive 
surgical margin carry poor prognosis and should be avoided by frozen 
section / histopathology of close or doubtful margin17,19. 
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 Primary reconstruction of surgical defects with well vascularized  
flaps should be done in most cases. This allows prompt healing, early 
resumption of function, effective rehabilitation and shorter hospital 
stay. 
Advantages 
o Many cancers of oral cavity are amenable to surgical excision 
per orally. 
o Surgical treatment is preferred in patients with advanced tumour 
and those with mandible invasion.16 
In a retrospective study of 105 patients who had resections of 
previously untreated squamous carcinomas that were 
localized to the oral tongue or the floor of the mouth, 80% 
had simple per oral excision. 93% of T1 and 78% of T2 
remained well after conservative operations (Ronald et al., 
2003).36 
o Requires less time and provides fewer long term sequelae.   
Disadvantages 
o Potential risk of anesthesia. 
o Functional disabilities. 
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Mandible involvement 
 Invasion of mandible is not radiocurable and can spread 
perineurally via inferior alveolar nerve. Direct invasion required 
hemimandibulectomy. Tumours approaching but not invading need 
marginal mandibulectomy.15   
Cervical Node Metastasis 
 When palpable nodes are present in the neck the decision to 
proceed with therapy may be made on purely clinical grounds. Palpable 
nodes require surgical therapy in some form of neck dissection, usually 
performed in continuity with the tumour. 
 High incidence of occult cervical metastases, even with small 
primary tumour and increased incidence of extracapsular spread in 
cases with palpable  adenopathy  provides a logical basis for treatment 
of the neck in a preclinical stage (Carl, E.S. 2002)37. 
Neck Dissection can be 
• Radical Neck Dissection – Crile (Fig. 14) 
• Modified Radical Neck dissection 
• Functional Neck dissection 
• Selective Neck dissection 
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Surgery in advanced Disease 
 Most efficient method is single stage reconstruction at the time 
of ablative surgery. Enormous advance in reconstructive techniques 
have affected mainly the efficiency of therapy in restoring the patient to 
reasonable function and appearance rapidly. The various flaps used in 
reconstructive method are  
¾ Tongue flap 
¾ Nasolabial flap 
¾ Forehead flap – McGregor 
¾ Bilobed forehead and scalp – Narayanan’s flap (Fig. 15) 
¾ Delto pectoral flap – Bakamjian  
¾ Pectoralis major myocutaneous flap 
¾ Trapezius myocutaneous flap 
¾ Sternomastoid flap 
¾ Lattismus dorsi flap 
¾  Free flaps 
 Flaps are tissue consisting of entire thickness of skin, plus 
variable amount of underlying tissue. With a network of blood vessels, 
arterial, capillary and venous and it is the effectiveness of the 
circulation through this network in perfusing the tissues of the flap 
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determines its survival. The defect in the donor area can be closed by 
direct suturing or with split skin graft. 
Fore head flap 
 The hairless skin of fore head is used mainly for covering intra 
oral defects. In females, it is also used for outer skin cover. It is 
laterally based from lateral border of eyebrow to the anterior margin of 
pinna, curving across the forehead. It is based on superficial temporal 
artery anterior branch. Flap is raised in the plane between pericranium 
and the aponeurosis, dissecting in the loose areolar  tissue.  
 Return of the bridge segment and insetting is done after about 10 
days when the flap gained vascularity from the local tissue.1 
Deltopectoral flap (Fig. 16) 
 This is an axial pattern flap based on first three or four 
perforating branches of Internalmammary artery. These arteries emerge 
from corresponding intercostal space close to the lateral border of 
sternum. They extend as far as the deltopectoral groove. It is usually 
used to cover extra oral defect, when the exposed bridge segment is 
tubed in order to eliminate raw surface. It is sometimes used for 
covering intra oral defect. 
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Pectoralismajor flap 
 Based on pectoral branch of acromio thoracic artery and its 
associated veins. Pectoral myocutaneous flap is tailored from below 
and medial to  nipple. Adequate size of skin, subcutaneous tissue and 
pectoralis muscle is raised with muscle pedicle measuring almost 
similar to the breadth of the island skin. This is tunneled through the 
lower neck incision, beneath the neck skin and brought into the mouth 
to cover the intra oral mucous membrane defect. 
 Bilobar Narayanan’s flap – forehead and scalp – is used for 
lining and cover in males. 
 The pectoralismajor myocutaneous flap for lining and 
deltopectoral flap for cover in females is used frequently.  
 
PRINCIPLES OF RADIOTHERAPY 
 Cancers of oral cavity are of particular importance to radiation 
oncologist. They have an active role in early and advanced disease. The 
intent of irradiation of head and neck is to ensure a long term and 
permanent locoregional tumour control.  
 Radiotherapy offers many head and neck cancer patients a valid 
alternative to mutilating surgical procedure and very often a better 
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quality of life than after functional conservation surgery. Radiotherapy 
causes destruction of neoplastic disease at both primary site and nearby 
microscopic extensions. RT includes multifield techniques, rotational 
therapy, shrinking field techniques and electron and brachy boost 
techniques. In addition radiation sensitizers and protectors, 
hyperthermia, newer fractionation schedules are increasingly being 
used. 
  Fractionation is the division of a dose of radiation into relatively 
small doses given over certain number of days. Fractionation allows 
time for the repair of sublethal damage of normal tissues between 
fractions, but it can also lead to repopulation of the tumour cells to 
progress from one stage of the cell cycle to another between fractions. 
Because tumour cells are more susceptible to the killing effects of 
ionizing radiation tumour cells spared during one fraction may in time 
be more susceptible during the next or subsequent fractions. In addition 
number of hypoxic tumour cells may decrease between successive 
fractions owing to reoxygenation. 
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Advantages  
• Major surgery is avoidable. 
• No tissues are removed and hence no functional or cosmetic 
effect.29 
• Elective irradiation of lymphnodes can be included with little 
added morbidity whereas a surgeon should adopt a ‘wait and see’ 
policy or proceed with elective neck dissection. 
• The surgical salvage of an irradiation failure is more likely to 
succeed than the salvage of a surgical failure. When irradiation is 
unsuccessful in creating a primary lesion, the cancer always 
recurs in the centre of the original lesion. But surgical 
recurrences are more likely to occur at the margins of the 
resection in or near the suture line. It is difficult to distinguish 
the normal surgical scar from recurrent disease and diagnosis of  
recurrence is often delayed.26 
• The total cost of radiation therapy is usually less than surgery. 
• Multiple primary lesions can be simultaneously encompassed. 
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Principles 
o The volume of primary tumour site which requires high dose of 
radiation must include a margin outside all cancer cells and is 
comparable to that which must be removed surgically. 
o Anatomic sites of actual or likely spread of cancer such as 
regional lymphnodes are frequently included in continuity with 
the primary tumour. 
o Post operative radiation after removal of all grossly detectable 
disease in a dose of 4500 – 6000 cGy result in very high 
frequency of tumour control with few detectable sequelae. 
 The standard radiation treatment regimen for head and neck 
cancer consists of 5 daily treatment fractions per week given for 5 to 7 
continuous weeks. The daily dose per fraction is 180 cGY to 225 cGY. 
Technique  
1. External Beam Radiotherapy (XRT) 
(i) XRT as sole treatment with curative intent and in clinically positive 
nodes. 70 – 75 Gy to the tumour, 65 – 70 Gy to the clinically 
positive nodes, Elective neck node irradiation 40 – 50 Gy 
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(ii) XRT with brachy therapy 
      XRT to tumour and primary nodes is started with a dose of 45 – 50 
Gy followed by an interstitial implant (1 – 2 weeks later) with 
iridium wires with a delivery dose of 25 – 30 Gy. 
(iii) XRT followed by surgery 
 50 Gy are given to the tumour site and neck nodes  
(iv) XRT preceded by surgery 
  When local resection is sufficient, no postoperative irradiation is 
given except in T4 where a dose of 60 Gy reduces risk of local 
recurrence. When there are positive nodes, 50 Gy is sufficient to 
control the neck nodes but may be increased to 60 Gy when there is 
capsular rupture or perineural spread or tumour spillage is 
suspected.25 
Advantages  
 Centripetal shrinkage of tumour. 
 Sterilizes lymphatics. 
 Allows adequate clearance. 
 Advantage in the posteriorly placed or ill defined primary that 
would make surgical exposure difficult. Functional disability 
(speech/ deglutition) is also less. 
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Disadvantages 
 Tumours that have deep invasion or are large (T3, T4) are less 
responsive to XRT. 
 Second course of XRT cannot be considered. 
 Salvage surgery for radiation failure is associated with lower 
survival and high morbidity.32 
 Side effects of irradiation like xerostomia, mucositis and 
osteoradionecrosis. 
 Long treatment time of 5 – 7 weeks can be a burden.  
 
2. Brachy Therapy 
 Indicated in well defined and accessible T1 and T2 tumour 
Advantage 
- Conservative treatment 
- Well defined volume of radiation 
Indications 
1. Tumour control 
 Small tumours T1 – T2 are equally well controlled by radio 
therapy or surgery. 
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2. Pre surgical  
 114 patients with squamous cells cancer of the oral cavity were 
evaluated in the Department of Radiation oncology at the university of 
Virginia, Majority were treated with radiation therapy alone, whereas 
the remainder were treated with radiation therapy preoperatively or 
postoperatively. 75 patients received external beam therapy and 32 
patients received an implant and   results studied (Leroy et al., 2001).40 
 A dose of 50 Gy is delivered to the primary tumour and regional 
nodes with double aim to reduce the tumour size and effect cell kill to 
facilitate ease of surgery.21 
3. Post surgical 
 51 patients with squamous cell Ca of oral tongue and floor of 
mouth were treated with combined surgery plus RT. This study 
highlights significant differences between floor of mouth and oral 
tongue cancers in response to combined surgery and RT (Zelefsky, M.J. 
2001).41 
 In complete resection (upto 60 – 70 Gy dose) is given, depending  
on the stage and grade of tumour. When elective neck dissection is first 
done, radio therapy is given depending upon the histological grade. 
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4. Elective treatment of clinically negative nodes 
 If a high rate of relapse is expected in neck nodes more than 90% 
of the cases can be prevented by delivery of 40 - 50 Gy to the neck. 
5. Relapsing tumour after surgery 
 When salvage surgery is not feasible salvage radiation therapy 
can be tried, although often with poor outcome due to tumour load, 
poor vascularization and patients general condition.33 
6. Palliation 
 When tumour is considered surgically or radiotherapeutically 
incurable, a few high dose fractions are given in order to reduce 
symptoms such as pain and bleeding. 
Side effects of Radio therapy 
Early 
a) Mucositis 
b) Dry mouth 
c) Loss of taste 
d) Dysphagia, Dyspnoea 
e) Erythema and Epidermolysis 
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Late  
a) Soft tissue necrosis, Flap dehiscence 
b) Osteoradionecrosis of mandible. This is predisposed by increased 
dose delivery to the mandible, mandibular parts not covered by 
healing mucosa and dental extraction within 10 days of 
brachytherapy. 
c) Hypothyroidism 
PRINCIPLES OF CHEMOTHERAPY 
 Patient with disseminated head and neck cancers usually die 
within 6 months. Several agents measurably shrink recurrent or 
disseminated head and neck cancers. Responses to CT are influenced 
by tumour grade and extent. 
 26 patients with advanced squamous cell cancer of head and 
neck were treated with bleomycin, oncovin, mitomycinC and 
methotrexate (BOMM) for 10 weeks. Partial and non responders 
received Adriamycin, cisplatin and cyclophosphamide (APC). The 
response rate to BOMM was 65% and to APC was 20% (Weeker et al., 
2002).42 
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Chemotherapy may be administered as 
 
1) Single agent 
 Cisplatin / 5 – FU / Methotrexate / Bleomycin are the single most 
effective agents 
2) Combination CT 
 The most effective combination regimen to date is cisplatin  and                  
5 – fluorouracil 
Other combinations are 
 5FU / Hydroxyurea 
 Cisplatin / Paclitaxel 
 Carboplatin  / Infusional 5FU 
 Cefuximab 
3) Post operative adjuvant  CT 
 No proven effect on disease free survival28 
 In Adjuvant chemotherapy for advanced head and neck 
squamous carcinoma, Head and neck contracts program, Potomac, 
administering  chemotherapy post operatively in patients with head and 
neck cancer fail to demonstrate significant clinical outcome, but distant 
metastasis rates may be reduced.  
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4) Preoperative Neoadjuvant CT 
 Can result in tumour regression in 60 – 90 percent and 
incomplete responses in 20 – 25 percent.22 
 Chemotherapy combined with irradiation produced improvement 
in median or overall survival in comparison to irradiation alone. Recent 
trials of chemotherapy used preoperatively in the treatment of head and 
neck cancer have not yielded decreased recurrence rates or increased 
overall survival rates in comparison to surgery alone, but they do 
appear to have prolonged the disease free interval following definitive 
surgery. (Green, M.R., 1998).43 
Various drugs used for chemotherapy 
Cisplatin 
 Dose : 50 – 100 mg / m2 BSA IV every 3 weeks 
5 – FU 
 Dose : 800 – 1000 mg / m2 BSA, IV, 3 – 5 days cycle every 28 
 days 
Methotrexate 
 Dose : 2.5 - 5 mg daily, po; or 40 mg / m2 IV weekly with 
 Leucoverin 
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Vincristine 
 Dose : 2 – 10 mg / m2 BSA, every 3 weeks 
Cyclophoshamide 
 Dose : 10 – 15 mg / kg IV every 2 – 3 weeks 
Mitomycin 
 Dose : 1.5 mg / m2 IV weekly 
Bleomycin 
 Dose : 10 – 20 mg / m2 IV once or twice weekly 
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MATERIALS AND METHODS 
 This study was conducted at Coimbatore Medical College 
Hospital from July 2006 to August 2008. 
 All the cases admitted in the surgical units were evaluated and 
studied. No specific criteria were used among the oral cancers. Under 
this study, all malignant neoplasm of lip, cheek, alveolus, tongue, floor 
of mouth and hard palate were included. 
 A careful recording of history symptoms, etiological factors and 
complications of oral cancers was elicited. A through clinical 
examination of the primary metastasis was also done and staged in 
TNM staging. 
 All patients underwent routine baseline investigations like urine 
for albumin and sugar, complete hemogram, blood for urea and sugar, 
serum for creatinine and bilirubin, chest x ray and ECG. All the 
patients were subjected to wedge biopsy of the lesion and 
histopathology examination of the specimen was carried out to assess 
the native and histological grading of the tumour. 
 
 
 
 44
Criteria for Response 
 Complete regression of tumour and nodes was taken as excellent 
response while presence of residual lesion was considered as partial 
response. 
Follow up 
 Complete regression of lesion was followed up with observation. 
Residual lesions were subjected to CT / RT. 
Limitations of study 
1. There was a very high drop out rate even at the initial stage of 
study. Some patients were not willing to salvage procedures. 
2. Because of short period available, patients could be followed up 
for a minimum period only. Hence adequate data regarding 
tumour free initial survival period and exact recurrence rates 
were not available. 
3. Since most of the patients present in late stage of disease, proper 
evaluation of treatment modalities in early stages could not be 
studied. 
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OBSERVATION AND ANALYSIS 
 A total of 325 patients were admitted in the surgical units and 
registered and treated by the Department of Oncology, Coimbatore 
Medical College and Hospital from July 2006 to August  2008. 
 The age wise distribution of oral cancer was studied. 
  Table : 1 
Age group 
in years 
Number % 
31 – 40 32 9.85 
41 – 50 75 23.00 
51 – 60 103 31.70 
61 – 70 83 25.50 
71 – 80 32 9.85 
TOTAL 325 100.00 
 As shown, the highest presentation was in the sixth decade of 
life, which amounted to  31.7 % of the cases. 
Table : 2 
Age 
group 
31 – 40 41 – 50 51 – 60 61 – 70 71 – 80 TOTAL
Male 14 34 53 44 16 161 
Female 18 41 50 39 16 164 
TOTAL 32 75 103 83 32 325 
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 There is no male or female predominance. Males had a 
predominance in the sixth and seventh decade of life while the female 
predominance was in the fifth and sixth decades. 
Table : 3 
Age group 31 – 40 41 – 50 51 – 60 61 – 70 71 – 80 
TOTA
L 
Male 14 34 53 44 16 161 
Female 18 41 50 39 16 164 
Male : Female 0.77 : 1 0.82 : 1 1.06 : 1 1.12 : 1 1 : 1 0.98 : 1
 
 The Male : Female ratio in this study was 0.98 : 1 ranging from 
0.77 to 1.12 :1. 
 On analysing the risk factors, the habit of betel leaf chewing and 
tobacco in its different forms amounted for majority of the cases. 
  Table : 4 - ANALYSIS OF RISK FACTORS 
B T S A B,T S,A B,S B,A S,T A,T B,S,T B,A,T S,A,T B,S,A,T 
No 
Risk 
Tot 
58 10 18 2 92 42 8 13 16 1 8 6 37 3 11 325 
B - Beta leaf and nut chewing 
T - Tobacco chewing 
S - Smoking 
A - Alcohol 
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  Table : 5 
SITE of lesion 
No. of 
patients 
% 
1. Buccal mucosa – Left 79 24.3 
2. Buccal mucosa – Right 69 21.2 
3. Tongue 97 29.85 
4. Alveolus 34 10.5 
5. Floor of mouth 15 4.6 
6. Hard palate 16 4.9 
7. Lip 15 4.6 
        TOTAL 325 100 
 The commonest site is the buccal mucosa, followed by the 
tongue, Alveolus, Hard palate, Floor of mouth and lips. The left side 
buccal mucosa showed a higher incidence, probably related to the habit 
of keeping the betel and tobacco quid in the mouth on the left side. 
 The commonest histologic type was squamous cell carcinoma, 
well differentiated type. 
 Table : 6 
Type Number  % 
Squamous cell carcinoma - Grade I 207 63.7 
Squamous cell carcinoma - Grade II 101 30.75 
Squamous cell carcinoma - Grade III 1 - 
Verrucous carcinoma 15 4.6 
Melanoma 1 - 
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 Majority of patients presented with advanced stage of disease. 
  Table : 7 
Stage Number % 
Stage I 3 1 
Stage II 25 7.7 
Stage III 102 31.4 
Stage IV 195 60 
 91.4% of the patients present with stage III and stage IV lesions, 
thus reflecting on the poor outcome. 
Table : 8 
Site T1 T2 T3 T4 TOTAL 
Buccal mucosa 4 28 42 74 148 
Tongue - 36 48 13 97 
Alveolus - 6 18 10 34 
Floor of mouth 1 4 4 6 15 
Hard palate - 2 4 10 16 
Lip - 6 6 3 15 
TOTAL 5 82 122 116 325 
 Analysing the primary tumour at presentation, it was observed 
that majority of the patients present with advanced disease. Majority of 
the patients presented with T3 and T4 lesions. 
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 Surgery was offered as primary treatment in 30 patients. Of these 
five patients had verrucous carcinoma and the rest had squamous cell 
carcinoma. 
     Table : 9 
Type Number % Surgery % 
Squamous cell carcinoma  309 95 25 8 
Verrucous carcinoma 15 4.6 5 33.3 
Melanoma 1 - - - 
Total 325 - 30 - 
 Surgery is the most effective modality of treatment for verrucous 
carcinoma. However as most of the squamous cell carcinoma patients 
report with advanced disease or opted for nonoperative management, 
only 8% of patients with squamous cell carcinoma underwent surgery. 
 Five patients underwent surgery for verrucous carcinoma. Four 
were not subjected to any adjuvant modalities. One patient who had 
recurrence was subjected to chemotherapy. 
Table :10 
Surgery Site Number Recurrences
Excision with primary closure R – Buccal 1 - 
Wide excision, segmental 
mandibulectomy, Deltopectoralflap 
L – Buccal 1 - 
Wide excision, Tongue flap cover (Fig. 17) L – Buccal 1 1 
Wide excision, Abbe’s flap Lip 1 - 
Wide excision, segmental 
mandibulectomy supra omohyoid 
dissection, Deltopectoralflap 
L – Buccal 1 - 
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 25 patients with squamous cell carcinoma were operated and the 
results discussed below. Only a few patients were operated upon 
because many patients opted for noninvasive therapies for fear of 
disfigurement and prolonged hospitalization or reported late making 
surgery difficult. 
Table :11    Surgery – Squamous cell carcinoma 
Buccal Mucosa Number Recurrences 
Excision with primary closure 3 - 
Wide excision with SSG 3 1 
Wide excision, Hemimandibulectomy, 
Deltopectoralflap (Fig. 18) 
2 - 
Wide excision, Hemimandibulectomy, forehead flap 1 - 
Tongue Number Recurrences 
Excision with primary closure 4 1  
Hemiglossectomy, Tongue Flap 4 - 
Hemiglossectomy, RND (Fig. 19) 2 - 
Hemiglossectomy, MRND  1 - 
Alveolus Number Recurrences 
Wide excision, Subtotal Maxillectomy (Fig. 21) 1 - 
Hemimandibulectomy, Deltopectoral flap 1 - 
Hard palate Number Recurrences 
Excision 1 - 
Lip Number Recurrences 
Wide excision, Modified Flap 1 - 
Floor of Mouth Number Recurrences 
Wide excision, Segmental Mandibulectomy, 
Nasolabial flap (Fig. 20) 
1 - 
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 The recurrences were subjected to chemotherapy and 
radiotherapy. The patient with ca tongue had progression of the disease 
and did not respond to any of the modalities. One case of ca buccal 
mucosa had neo adjuvant chemotherapy with 2 cycles of cisplatin and 5 
fluorouracil. 14 patients received, chemotherapy and radiotherapy after 
surgery and 9 patients received chemotherapy alone. The number of 
patients operated were less and so the outcome of the surgery could not 
be assessed.  
 
Table : 12 
Surgery 
Post surgery 
CT 
Post surgery 
RT 
Post surgery 
CT + RT 
 No % No % No % 
30 9 30 1 3 14 47 
 
 Majority of the patients were subjected to chemotherapy and 
loco regional radiotherapy for efficient control. Out of 5 patients 
operated for verrucous carcinoma, 4 didnot undergo any adjuvant 
modalities. One had recurrence and was given chemotherapy. 
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 Chemotherapy was administered as either primary CT, adjuvant 
CT or salvage CT. The response to these modalities is as noted. 
         Table : 13 
Primary CT Failure Regimen No % No % 
Inj. Cisplatin D1, D2 
Inj. 5FU D1 – D3 
55 45 10 18 
Inj.cisplatin D1, D2 19 15.5 10 53 
Inj. MitomycinC D1 
Inj.  5FU D1 – D3 
10 8   
Inj. Vincristin D1 
Inj. Cyclophosphamide D1 
29 24 2 7 
Inj. Mitomycin C D1 
Inj. Cyclophosphamide D1 
3 2.5 - - 
Inj. Methotrexate D1 
Inj. Cyclophosphaomide D1 
6 5 - - 
        Table : 14 
Adjuvant  CT Failure Regimen No % No % 
Inj. Cisplatin D1, D2 
Inj. 5FU D1 – D3 
54 54 6 11 
Inj.cisplatin D1, D2 20 20 4 20 
Inj. MitomycinC D1 
Inj.  5FU D1 – D3 
- - - - 
Inj. Vincristin D1 
Inj. Cyclophosphamide D1 
20 20 2 20 
Inj. Mitomycin C D1 
Inj. Cyclophosphamide D1 
- - - - 
Inj. Methotrexate D1 
Inj. Cyclophosphamide D1 
6 6 1 - 
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 Various regimens were used, subject to the availability of the 
drugs in the hospital. The highest failure rates were seen in the single 
drug regimen. Multiple drug regimen had lower failure rates (7 – 20%). 
The failures were subjected to radiotherapy and T. Methotrexate 100 
mg/day for 2 weeks, every 3 weeks. There was also a high rate of 
defaulters among the patients. This was due to prolonged treatment 
strategies, ignorance and illiteracy, patients not understanding the 
importance of chemotherapy. 
 Radiotherapy was also administered either as primary or 
palliative treatment. The patients were subjected to Telecobalt external 
beam radio therapy, at 200 – 220 cGy, 5 daily fractions per week, 28 to 
35 sittings. 
Table :15 
Site Primary RT Complete Response % of failure
Buccal Mucosa 38 20 47 
Tongue 12 5 58 
Alveolus 8 5 37 
Floor of mouth 8 6 25 
Hard palate - - - 
Lips - - - 
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Table :16 
Site Palliative RT Complete Response % of failure
Buccal Mucosa 20 14 30 
Tongue 12 4 67 
Alveolus - - - 
Floor of mouth - - - 
Hard palate - - - 
Lips - - - 
 Good response to treatment was achieved in T1 and T2 diseases 
while the response was poor in late lesions. 
 Multimodal treatment strategy was more beneficial than single 
modality and a majority of patients received multimodal treatment 
strategies. 
Table : 17 
Positive 
response 
Failure Default 
Regimen No 
No % No % No % 
Surgery + CT + RT 16 14 81.5 1 6.25 1 6.25
CT + Surgery 8 6 75 1 12.5 1 12.5
CT + RT 152 98 65 49 32 5 3 
Surgery 6 4 66.5 1 16.5 1 16.5
 The response was better with multimodality treatment. This is 
because the three modalities act synergistically in controlling both the 
local and regional metastasis. 
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     Table :18 
Cases Defaulters % 
325 122 37 
  There was also a high rate of defaulters among these 
patients. This was due to long treatment periods, very slow response to 
therapy and numerous side effects of treatment regimens and the 
morbidity associated with operative management making the male 
patient, who many times is the sole bread winner of the family avoid 
treatment. 
Results of the study 
1. Number of patients with oral malignancy studied  : 325 
2. Number of patients taken up for surgery   : 30 
3. Number of patients who had primary Radiotherapy  : 66 
4. Number of patients who had palliative radiotherapy : 32 
5. Number of patients who had primary chemotherapy : 122 
6. Number of patients who had multimodal treatment  : 176 
7. Number of patients who had recurrence   : 6 
8. Number of patients who had defaulted treatment  : 122 
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DISCUSSION 
 In the study conducted, oral malignancies accounted to 9.2% of 
all malignancies. The Alberta cancer registry figures show the 
incidence around 2%. The incidence of oral cancers in United States is 
3% of all cancer cases. 
Table : 1 
0
1
2
3
4
5
6
7
8
9
10
Alberta United States Present study  
  
Study % 
Alberta 2 
United States 3 
Present study 9.2 
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 In the present study, majority of the patients present in their sixth 
and seventh decades. In the Alberta cancer registry, the maximum 
incidence was in the fifth and sixth decade. In United States, the 
average age of onset was fifth decade. 
Table : 2 
Study Age (Decade)
Alberta 5th, 6th 
United States 5th 
Present study 6th, 7th 
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 The Male : Female ratio in this study was 0.98 : 1. The ratio in 
Alberta study was 2:1 and in United States the ratio was 3:1. 
Table : 3 
Study M : F
Alberta 2:1 
United States 3:1 
Present study 0.98:1
 
 
0.00
0.50
1.00
1.50
2.00
2.50
3.00
Alberta United States Present study
 
 
 This may be attributed to increased exposure to betelnut and 
tobacco in females. Fewer males chewed betelnut and tobacco. 
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 The commonest site was buccal mucosa followed by tongue, 
Alveolus, Hard palate, floor of mouth and lip. In both the Alberta and 
United States study, the commonest site is buccal mucosa  followed by 
tongue, lip, floor of mouth, Alveolus and Hard palate. 
Table : 4 
Study 
Buccal 
Mucosa 
Tongue Alveolus FOM HP Lip 
Alberta 29.5% 23% 6.5% 15.5% 5% 20% 
United States 28% 24% 9% 12% 4% 22% 
Present study 53.5% 29.8% 10.5% 4.6% 4.9% 4.6%
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 Squamous cell carcinoma was the commonest type 95% 
followed by verrucous carcinoma 4.6%. There was one case  of 
Melanoma of hard palate. This was comparable to the results of the 
other studies where the incidence was 88% and 90% respectively.  
Table : 5 
Study % 
Alberta 88 
United States 90 
Present study 95 
84
86
88
90
92
94
96
Alberta United States Present study
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 Most of the patients presented late and hence the results of 
surgery could not be compared effectively. 
Table : 6  
Treatment  No % failure 
Surgery 6 1    (16.5%) 
Surgery + CT 8 1    (12.5%) 
Surgery + CT + RT 16 1   (6.25%) 
0.00
3.00
6.00
9.00
12.00
15.00
18.00
Total No. of failure % of failure
Surgery Surgery + CT Surgery + CT + RT
 
 Radiotherapy was used as the first line of management of 
carcinoma of buccal mucosa in a series by M. Krishnan Nair and R. 
Sankaranarayanan which showed 85% with Stage I, 63% with Stage II, 
41% with Stage III  and 15% with Stage IV disease survived disease 
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free at 3 years.35 In our study, Radiotherapy was  used in 38 cases of 
buccal mucosa Ca, 12 cases  of tongue Ca, 8 cases of Alveolus Ca, 8 
cases of floor of mouth Ca followed by chemotherapy with 47% failure 
for buccal mucosa Ca, 58% failure for tongue Ca, 37% failure for 
Alveolus and 25% failure for floor of mouth Ca. 
 Surgical treatment for T1 – T2 patients with the addition of 
postoperative twice a day radiotherapy is recommended in  selected 
cases. For T3 – T4 patients twice a day preoperative radiotherapy is 
recommended as it reduces the extent of the surgical  procedure 
(Fein et al., 2002)44.  
 Single modality treatment with surgery or radiotherapy is 
generally recommended for the patients who present with early stage 
disease Stage I and II. The 2 modalities result in similar survival in 
these individuals. In contrast, in patients with locally advanced disease 
at diagnosis, combined modality therapy is recommended. 
Unfortunately the majority of oral cancers present at an advanced Stage 
III and IV, when therapy is more complex and the prognosis is worse.30 
A combination of surgery and radiation therapy provides the best 
survival rate although this increases the complication and morbidity. 
Role of chemotherapy has not been clearly defined in oral squamous 
cell carcinoma. 
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SUMMARY AND CONCLUSIONS 
 Three hundred and twenty five patients were treated at the 
Government Coimbatore Medical College Hospital during the 
period from July 2006 to August 2008. 
 Highest incidence of oral cancer was seen in the sixth decade of 
life and male female ratio being 0.98 : 1. 
 The buccal mucosa is the most common site. 148 out of 325 
patients had buccal carcinoma. 
 Multimodal treatment had  a better cure rate compared to single 
modality treatment. 16 patients were treated with surgery, CT 
and RT and there was only one recurrence within one year.  
 Combination chemotherapy was more effective than single 
agents and cisplatin and 5–Fluorouracil was the most effective 
combination. In the combination chemotherapy, the failure rate 
was 11 – 18 percent compared to the single agent chemotherapy 
where the failure rate was 20 – 53 percent. 
 Radiotherapy is more effective in the early stages and in 
combination with other modalities in late stages.  
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PROFORMA 
 
NAME    AGE      SEX OCCUPATION 
 
                      INCOME 
 
ADDRESS    OP / IP      UNIT 
  
 
 
 
 
DOA     DOS        DOD 
 
DIAGNOSIS 
 
 STAGE   TNM 
      
 
 EARLY 1 & II 
 
 LATE 
 
ANY   PREVIOUS     TREATMENT   :   YES / NO 
 
            DETAILS : 
SYMPTOMS : 
1. ULCER / SWELLING / GROWTH 
2. PAIN 
3. BLEEDING 
4. EXCESSIVE SALIVATION 
5. DYSPHONIA 
6. ALTERATION  IN  TASTE 
7. LOSS OF WT / APPETITE 
8. TRISMUS 
9. RECENT DENTAL EXTRACTION 
10. ANY OTHER SYMPTOM 
 
PAST H/O 
- H / O PREVIOUS SURGERY 
- H / O ORAL CANDIDIASIS  
- H / O ANY SYSTEMIC DISEASE DM / HT / TB 
- H / O IRRADIATION 
 
PERSONAL H/O 
- SMOKING 
- ALCOHOL 
- BETEL NUT / TOBACCO CHEWING 
- SHARP TEETH / DENTURES 
- CHRONIC ORAL SEPSIS 
- SPICY FOOD INTAKE 
- RADIATION EXPOSURE 
 
FAMILY H/O 
OCCUPATIONAL H/O 
TREATMENT H/O 
GENERAL EXAMINATION 
  - BUILD / NOURISHMENT 
  - PALLOR 
  - GEN. LYMPHADENOPATHY 
  - PULSE 
  - B.P 
  - ICTERUS 
 
EXAMINATION  OF  ORAL  CAVITY 
 
INSPECTION 
         SITE – LIPS, CHEEK, ALVEOLUS, TONGUE, FLOOR OF MOUTH,           
PALATE 
         PREMALIG LESIONS – LEUKOPLAKIA,  ERYTHROPLAKIA,    
                   SUBMUCOUS FIBROSIS 
 SIZE, EXTENT 
 MOUTH OPENING 
 ORAL HYGIENE 
 DENTAL FORMULA 
 
PALPATION 
 TYPE 
 SITE & SIZE 
 EXTENT 
 TENDERNESS 
 FLOOR & BASE 
 BLEEDS ON TOUCH 
 OROCUTANEOUS FISTULA 
NODAL STATUS 
 
OTHER SYSTEMS 
 
STAGE  : 
INVESTIGATION : 
1. URINE - ALB 
  - SUGAR 
  - DEPOSITS 
2. CHG 
3. BLOOD - UREA 
  - SUGAR 
4. S.CREATININE 
5. S.VDRL 
6. X-RAY  MANDIBLE 
7. X-RAY  CHEST 
8. ORTHOPANTOMOGRAM 
9. CT – SCAN 
10. BIOPSY 
11. FNAC OF NODE 
TREATMENT : 
 CURATIVE / PALLIATIVE 
 NEOADJUVANT THERAPY 
 SURGERY DONE  : 
    
 RT – CURATIVE / PALLIATIVE 
 CT – DRUGS, CYCLES, RESPONSE 
OUTCOME 
FOLLOW UP 
MASTER CHART 
S. 
NO NAME AGE 
S
E
X
 
REG. 
NO 
RISK 
FA SITE TYPE 
G
R
A
D
E
 
TNM PRIM TT SURG FOLL UP 
1 RANGAMMAL 60 F 954/06 B, T L-BUCCAL SCC I T3 N0 M0 CT  Asymp 
2 SARASWATHY 60 F 999/06 B, T R-BUCCAL SCC I T4 N1 M0 CT+RT  Progr 
3 SWAMIATHAL 65 F 1019/06 B, T TONGUE SCC II T2 N1 M0 CT+RT  Defau 
4 KANNAN 55 M 1055/06 S, A FOM SCC I T4 N1 M0 CT  Progr 
5 GNANAMMAL 55 F 1066/06 B,T R-BUCCAL SCC II T3N1 M0 CT+RT  Defau 
6 MARUTHACHALAM 55 M 1083/06 B,A,T R-BUCCAL SCC I T4 N1 M0 CT  Defau 
7 DURAIRAJ 39 M 1094/06 S, A L-BUCCAL SCC I T2 N0 M0 SY+ CT+RT WE, SSG Asymp 
8 MUTHAN 55 M 1099/06 S, A HARD PAL SCC I T3 N2 M0 CT+RT  Progr 
9 ARUMUGAM 64 M 1106/06 A HARD PAL MM  T4 N0 M0 RT  Defau 
10 KRISHNASWAMY 72 M 1109/06 S, A FOM SCC I T3 N0 M0 CT  Asymp 
11 NATARAJ 75 M 1114/06 S, A TONGUE SCC II T4N1M0 CT + RT  Asymp 
12 THULASIAMMAL 60 F 1120/06 B L-BUCCAL SCC I T3N1M0 CT  Defau 
13 ARUMUGAM 75 M 1121/06 A TONGUE SCC I T2N2M0 CT + RT  Progr 
14 RENGAMMAL 70 F 1149/06 B TONGUE SCC II T4N1M0 CT + RT  Defau 
15 LAKSHMI 55 F 1160/06 T TONGUE SCC I T3N2M0 CT + RT  Recur,CT 
16 NAGAVANI 54 F 1164/06 T TONGUE SCC I T3N1M0 CT + RT  Defau 
17 VALPURAMMAL 60 F 1175/06 B, T L-BUCCAL VC  T4N1M0 CT + RT  Asymp 
18 KUMARASWAMY 55 M 1182/06 B, A R-BUCCAL SCC I T2N0M0 CT  Asymp 
19 MAHALI 40 F 1186/06 B R-BUCCAL SCC I T4N0M0 CT + RT  Defau 
20 THIRUMOORTHY 50 M 1187/06 B, S L-BUCCAL SCC II T3N0M0 CT  Asymp 
21 THANNASI 44 M 1190/06 B, S R-BUCCAL SCC I T4N1M0 CT + RT  Defau 
22 HUSSAIN 46 M 1196/06 B, S R-BUCCAL SCC II T3N1M0 CT  Defau 
23 CHELLAMMAL 55 F 1282/06 B, S L-BUCCAL SCC I T2N1M0 CT + RT  Asymp 
24 RAPPAL 80 F 1291/06 T HARD PAL SCC I T3N0M0 CT  Deafu 
25 PERIYAMMAL 47 F 1295/06 B, T L-BUCCAL SCC I T4N1M0 CT + RT  Progr 
26 VAIYAPURI 45 M 1309/06 S, A TONGUE SCC II T2N0M0 SY + CT + RT WE, PC Asymp 
27 RAMASWAMY 70 M 1314/06 S, A LIP SCC I T4N1M0 CT + RT  Asymp 
28 SUBRAMANI 60 M 1315/06 S, A TONGUE SCC II T2N0M0 SY + CT WE, PC Asymp 
29 MUNIAMMAL 65 F 1324/06 B, T R. BUCCAL SCC I T4N0M0 CT  Defau 
30 DURAISAMY 62 M 1335/06 B,A,T L. BUCCAL SCC II T3N0M0 CT  Defau 
31 MANIMARAI 80 M 1356/06 S, A TONGUE SCC I T4N1M0 CT + RT  Asymp 
32 PITCHAI 55 M 1362/06 S, A LIP SCC II T2N1M0 CT + RT  Asymp 
33 RAMASWAMY 60 M 1383/06 S, A FOM SCC I T4N1M0 CT  Progr 
34 PERUMAL 45 M 1388/06 S, A FOM SCC I T3N1M0 CT  Defau 
35 SUBRAMANI 47 M 1390/06 S, A TONGUE SCC I T3N2M0 CT + RT  Asymp 
36 DEVARASI 33 F 1471/06 B, T L. BUCCAL SCC II T3N2M0 CT + RT  Defau 
37 RUKUMANI 65 F 1472/06 B, T  ALVEOLUS SCC I T3N0M0 CT + RT  Asymp 
38 KALIAMMAL 48 F 1480/06 B, T  L. BUCCAL SCC II T4N1M0 CT + RT  Progr 
39 BASHA 70 M 1497/06 S, A ALVEOLUS SCC I T4N0M0 CT  Asymp 
40 ANGATHAL 60 F 1511/06 B, T R. BUCCAL SCC II T3N2M0 CT + RT  Asymp 
41 KAMACHI 75 F 1539/06 B, T TONGUE SCC I T2N0M0 SY + CT WE, PC Recur 
42 RAMASWAMY 50 M 1545/06 S, A TONGUE SCC I T3N1M0 CT  Defau 
43 MANOOP 55 M 1566/06 S, A,T L. BUCCAL SCC I T4N1M0 CT + RT  Progr 
44 LAKSHMI 40 F 1568/06 B L. BUCCAL SCC II T2N1M0 CT + RT  Asymp 
45 RAJAMMAL 80 F 1582/06 B ALVEOLUS SCC I T4N1M0 CT  Defau 
46 ANGATHAL 50 F 1586/06 B, T R. BUCCAL SCC I T3N2M0 CT + RT  Asymp 
47 JAITHOONBEE 75 F 1616/06 T LIP VC  T4N1M0 CT  Asymp 
48 ASIYA 52 F 1623/06 B, T L. BUCCAL SCC I T3N2M0 CT + RT  Progr 
49 ARAL 50 F 1629/06 B, T L. BUCCAL SCC II T3N0M0 CT  Asymp 
50 PATTU 64 M 1646/06 B, A L. BUCCAL SCC I T3N2M0 CT + RT  Defau 
51 RAMASWAMY 75 M 1654/06 S, A L. BUCCAL SCC II T3N2M0 SY + CT + RT WE,HM,DPF Defau 
52 JAITHOOMBEE 75 M 1656/06 B, A R. BUCCAL SCC I T3N1M0 CT  Defau 
53 MUTHUSWAMY 70 M 1734/06 S, A,T R. BUCCAL SCC II T4N1M0 CT + RT  Defau 
54 NATARAJAN 59 M 1739/06 S, A LIP SCC I T4N0M0 CT  Asymp 
55 LAKSHMI 43 F 1753/06 B, T TONGUE SCC I T4N2M0 CT + RT  Progr 
56 KARUPATHAL 45 F 1762/06 B, T R. BUCCAL VC  T2N0M0 SY WE, PC asymp 
57 POOVATHAL 48 F 1773/06 B R. BUCCAL SCC I T3N2M0 CT + RT  Defau 
58 KALYANASUNDARAM 48 M 1776/06 S, A TONGUE SCC I T2N1M0 CT  Asymp 
59 KANAGARAJ 40 M 1/07 S TONGUE SCC I T4N1M0 CT + RT  Defau 
60 PITCHAIAH 58 M 9/07 S, T TONGUE SCC I T3N0M0 SY + CT + RT HG, TF Asymp 
61 SANKARAL 55 F 18/07 B, T R. BUCCAL SCC I T4N1M0 CT  Asymp 
62 ARULMATHY 60 F 38/07 B, T ALVEOLUS  SCC II T3N0M0 CT  Asymp 
63 SIVAKAMI 40 F 45/07 B, T L. BUCCAL SCC I T3N2M0 CT + RT  Progr 
64 SARASWATHY 33 F 57/07 B, T TONGUE SCC II T2N1M0 CT  Defau 
65 PERIYASWAMY 65 M 82/07 S, A, T FOM SCC I T4N1M0 CT + RT  Defau 
66 IYYASWAMY 69 M 86/07 S, A, T ALVEOLUS SCC I T2N0M0 CT  Asymp 
67 SUBBIAH 76 M 88/07 B, A R. BUCCAL SCC II T4N2M0 CT + RT  Recur 
68 DAVID 60 M 92/07 S, A R. BUCCAL SCC I T3N1M0 CT + RT  Asymp 
69 CHANDARAN 48 M 102/07 S, A TONGUE SCC II T4N1M0 CT + RT  progr 
70 ALAUDDIN 45 M 141/07 S R. BUCCAL SCC I T4N0M0 CT  Asymp 
71 DEIVAMANI 40 F 152/07 B, T TONGUE SCC II T2N2M0 SY+ CT + RT HG, RND Defau 
72 CHANDRAN 45 F 159/07 B, T TONGUE SCC I T3N2M0 CT + RT  Defau 
73 VIJAYA 70 M 166/07 B, A R. BUCCAL SCC II T2N2M0 SY+ CT + RT WE, PC Asymp 
74 JEGANATHAN 32 M 168/07 S, T TONGUE SCC I T4N1M0 CT + RT  Defau 
75 RENGAMMAL 80 F 194/07 B, T R. BUCCAL SCC I T2N2M0 CT + RT  Progr 
76 GOUNDAN 65 M 202/07 B, A R. BUCCAL SCC I T3N1M0 CT  Asymp 
77 KAVITHAL 50 F 204/07 B, T L. BUCCAL SCC I T3N2M0 CT + RT  Defau 
78 KARUPPASWAMY 48 M 235/07 S ALVEOLUS SCC II T4N1M0 CT  Defau 
79 SAMPATH 57 M 240/07 S FOM SCC I T4N0M0 CT + RT  Asymp 
80 VENKITAMMAL 70 F 248/07 T ALVEOLUS SCC I T2N2M0 CT + RT  Defau 
81 POOVATHAL 60 F 254/07 B, T L. BUCCAL SCC I T2N1M0 CT  Asymp 
82 KRISHNASWAMY 52 M 261/07 S,A ALVEOLUS SCC I T3N0M0 CT + RT  Defau 
83 VISWANATHAN 70 M 274/07 S, T HARD PAL SCC II T4N1M0 CT  Asymp 
84 SUNDARI 65 F 285/07 B, T L. BUCCAL SCC I T3N1M0 CT  Asymp 
85 SUBRAMANI 55 M 306/07 S, A TONGUE SCC II T3N2M0 CT + RT  Progr 
86 GOVINDASWAMY 80 M 325/07 S, A TONGUE SCC I T4N1M0 CT  Defau 
87 UTHANTHIGOUNDER 80 M 350/07 B, T R. BUCCAL SCC I T4N1M0 CT + RT  Asymp 
88 NAGAPPAN 55 M 325/07 B, A L.BUCCAL SCC II T2N1M0 CT + RT  Progr 
89 KANNYAMMAL 41 F 358/07 T LIP VC  T2N2M0 CT  Defau 
90 SELVI 34 F 375/07 B, T L. BUCCAL SCC I T2N2M0 CT + RT  Asymp 
91 SAKTHIVEL 43 M 406/07 S, A TONGUE SCC II T3N2M0 CT  Defau 
92 RAMASWAMY 64 M 407/07 S, T TONGUE SCC I T4N1M0 CT  Defau 
93 GOVINDARAJ 60 M 411/07 S, A LIP SCC II T4N0M0 CT + RT  Asymp 
94 SELVARAJ 38 M 412/07 B, A TONGUE SCC I T3N0M0 CT  Defau 
95 KALYANASUNDARAM 48 M 417/07 B, T L. BUCCAL VC  T3N0M0 SY WE,SM,DPF Asymp 
96 PASUPATHY 49 F 425/07 B, T R. BUCCAL SCC I T2N0M0 SY + CT WE, PC Asymp 
97 MARDUCHALAM 55 M 428/07 S, A, T TONGUE SCC I T4N1M0 SY + CT + RT HG, TF Defau 
98 KALIDAS 46 M 436/07 B, T R. BUCCAL SCC II T2N1M0 CT  Asymp 
99 KALLAN 60 M 454/07 S, A HARD PAL SCC I T3N0M0 CT  Asymp 
100 PITCHAIAMMAL 45 F 464/07 B, T L. BUCCAL SCC II T2N2M0 CT + RT  Defau 
101 SUBRAMANI 45 M 509/07 S, A, T TONGUE SCC I T2N2M0 SY + CT + RT HG, RND Defau 
102 KAMACHI 47 F 518/07 B, T L. BUCCAL SCC II T3N1M0 CT  Asymp 
103 MANIYAMMAL 40 F 532/07 T TONGUE SCC I T2N2M0 CT + RT  Progr 
104 BHAVANI 43 F 555/07 B L. BUCCAL  SCC II T2N0M0 SY +CT + RT WE, PC Defau 
105 VELLINGIRI 31 M 561/07 B, A,T L. BUCCAL SCC I T4N1M0 CT + RT  Asymp 
106 VARDTHAPPAN 62 M 563/07 B R. BUCCAL SCC II T2N2M0 CT  Recur 
107 RAJESWARI 36 F 579/07 B ALVEOLUS SCC I T4N0M0 CT + RT  Asymp 
108 PONNAYEE 65 F 580/07 B L. BUCCAL SCC I T4N1M0 CT + RT  Defau 
109 VAIAPURI 41 M 624/07 S, A, T LIP SCC II T3N0M0 CT + RT  Defau 
110 MANOHARAN 55 M 627/07 S, A, T TONGUE SCC I T4N4M0 CT  Progr 
111 PAPATHY 45 F 632/07 T L. BUCCAL SCC I T2N1M0 CT + RT  Asymp 
112 RUKUMANI 65 F 659/07 B, T ALVEOLUS SCC I T2N2M0 CT  Defau 
113 PALANISAMY 46 M 660/07 A, T TONGUE SCC II T3N1M0 CT + RT  Asymp 
114 MUTHUSAMY 74 M 666/07 S ALVEOLUS  SCC I T2N2M0 CT + RT  Progr 
115 JOTHIMANI 35 F 680/07 T TONGUE SCC I T4N0M0 CT  Asymp 
116 PALANIAMMAL 55 F 683/07 B, T L. BUCCAL SCC II T4N1M0 CT  Asymp 
117 CHINNASWAMY 48 M 685/07 S ALVEOLUS  SCC I T2N0M0 CT  Asymp 
118 PONNUSWAMY 65 M 696/07 S, A TONGUE SCC I T2N2M0 CT + RT  Defau 
119 DHARMALINGAM 65 M 701/07 S, A HARD PAL SCC I T3N0M0 CT  Asymp 
120 SHANTHAMANI 59 F 704/07 B ALVEOLUS SCC I T2N2M0 CT + RT  Progr 
121 PERUMAL 70 M 707/07 S TONGUE SCC II T3N1M0 CT  Defau 
122 SARATHA 55 F 716/07 B, T R. BUCCAL SCC I T2N2M0 CT + RT  Defau 
123 RUKUMANI 50 F 717/07 B ALVEOLUS SCC II T4N1M0 CT + RT  Asymp 
124 THULSIAMMAL 50 F 718/07 T ALVEOLUS SCC I T2N1M0 CT  Defau 
125 VASANTHAMANI 50 F 720/07 B, T L LIP VC  T2N2M0 CT  Progr 
126 PAPATHY 59 F 727/07 B, T L. BUCCAL SCC I T2N0M0 SY + CT WE, SSG Asymp 
127 NAGAMMAL 80 F 729/07 B R. BUCCAL SCC II T4N1M0 CT + RT  Defau 
128 RAJAMMAL 65 F 743/07 B, T L. BUCCAL VC  T4N1M0 CT  Defau 
129 RAMATHAL 70 F 746/07 B L. BUCCAL SCC I T4N1M0 CT + RT  Asymp 
130 VELUSAMY 49 M 750/07 B, A TONGUE SCC I T3N0M0 CT  Asymp 
131 AMARAVATHY 55 F 753/07 B, T R. BUCCAL SCC I T4N1M0 CT  Asymp 
132 NANJAMMAL 62 F 754/07 B, T FOM SCC II T2N0M0 CT + RT  Asymp 
133 PALANIAMMAL 65 F 755/07 B L. BUCCAL VC  T3N2M0 CT  Defau 
134 MANI 60 M 767/07 B,A, T R. BUCCAL SCC I T4N0M0 CT  Defau 
135 MATHU 45 M 771/07 B, T R. BUCCAL SCC II T3N0M0 SY+ CT + RT WE, SSG Recur 
136 MUTHULAKSHMI 47 F 787/07 B, T L. BUCCAL SCC I T4N1M0 CT + RT  Asymp 
137 MANIYAMMAL 55 F 788/07 B ALVEOLUS SCC II T2N1M0 CT  Asymp 
138 KUPPUSAMY 80 M 792/07 S, A, T R. BUCCAL SCC I T2N2M0 CT  Progr 
139 JOHNBEFI 55 F 798/07 B, T L. BUCCAL SCC II T4N1M0 CT + RT  Asymp 
140 VENKATACHALAM 70 M 827/07 S, A TONGUE SCC I T3N1M0 CT + RT  Defau 
141 CHELLAPPAN 65 M 832/07 S, T TONGUE SCC I T2N2M0 CT  Progr 
142 SUBBAMMAL 48 F 850/07 B, T R. BUCCAL SCC II T4N0M0 CT + RT  Asymp 
143 KALIAMMAL 70 F 855/07 B, T ALVEOLUS SCC I T4N1M0 CT  Defau 
144 KRISHNASWAMY 65 M 861/07 S, A TONGUE SCC II T3N0M0 CT + RT  Asymp 
145 KRISHNAN 54 M 879/07 S, T TONGUE SCC I T3N2M0 CT  Progr 
146 MOHAMDJEBARULLA 40 M 880/07 S, A R. BUCCAL SCC I T3N1M0 CT + RT  Asymp 
147 SUBBAYYAN 60 M 885/07 S, T TONGUE SCC II T2N1M0 CT  Defau 
148 RAMATHAL 52 F 894/07 B, T L. BUCCAL SCC I T3N2M0 CT + RT  Progr 
149 VALLIAMMAL 60 F 903/07 B R. BUCCAL SCC I T4N1M0 CT  Asymp 
150 AMMASIKUTTY 45 M 904/07 S, A, T L. BUCCAL SCC I T3N0M0 CT  Asymp 
151 APPATHAL 60 F 920/07 B L. BUCCAL VC  T2N2M0 CT + RT  Defau 
152 LAKSHMI 40 F 951/07 B FOM SCC I T1N0M0 SY+ CT WE,SM,NLFC Asymp 
153 UMA 35 F 956/07 B R. BUCCAL SCC I T3N2M0 CT + RT  Progr 
154 APPU 65 M 960/07 S, T TONGUE SCC II T4N1M0 CT  Defau 
155 JANAKI 70 F 962/07 B R. BUCCAL SCC I T4N1M0 CT + RT  Asymp 
156 SELVARAJ 32 M 970/07 S, A, T TONGUE SCC II T2N2M0 CT  Defau 
157 VALLI GOUNDER 80 M 980/07 B, T HARD PAL SCC I T4N2M0 CT + RT  Defau 
158 GOVINDARAJ 57 M 1004/07 S TONGUE SCC I T3N2M0 CT  Defau 
159 CHINNASWAMY 35 M 1035/07 S, T HARD PAL SCC II T1N0M0 SY EXCI Asymp 
160 VADIVEL 45 F 1046/07 B TONGUE SCC I T3N1M0 CT + RT  Defau 
161 GOUNDAN 55 M 1052/07 S FOM SCC II T4N1M0 CT  Defau 
162 ESWARAN 36 M 1054/07 S, A, T L. BUCCAL VC  T2N1M0 SY WE,SM,SOD,DPF Asymp 
163 AMIRTHAVENI 58 F 1063/07 B HARD PAL SCC I T4N0M0 CT + RT  Asymp 
164 RENGANAYAKI 44 F 1096/07 B L. BUCCAL SCC I T4N1M0 CT + RT  Defau 
165 NACHIMUTHU 73 M 1100/07 B,A, T TONGUE SCC I T3N0M0 CT  Asymp 
166 LAKSHMI 55 F 1107/07 B ALVEOLUS SCC I T2N0M0 CT  Asymp 
167 GOPAL 61 M 1112/07 S, A, T ALVEOLUS SCC II T4N1M0 CT  Asymp 
168 CHELLAM 60 F 1115/07 B, T TONGUE SCC I T2N1M0 CT  Defau 
169 DEVAIMMAL 41 F 1116/07 B, T ALVEOLUS SCC II T3N2M0 CT + RT  Progr 
170 NAGAVAI 62 M 1118/07 S, A, T TONGUE SCC I T3N0M0 SY + CT + RT  HG, TF Asymp 
171 MOHAMED 56 M 1140/07 S, A, T TONGUE SCC I T4N1M0 CT + RT  Defau 
172 PALANISWAMY 61 M 1164/07 S, A L. BUCCAL SCC I T4N0M0 CT  Asymp 
173 DEVARAJ 65 M 1188/07 B, S R. BUCCAL SCC II T3N2M0 CT + RT  Defau 
174 PATHYAPPAN 60 M 1193/07 S, A TONGUE SCC I T4N1M0 CT  Asymp 
175 ANANTHA 53 M 1209/07 S TONGUE SCC I T2N2M0 CT + RT  Progr 
176 SUBRAMANYAN 63 M 1211/07 S, A, T TONGUE SCC II T3N1M0 CT  Defau 
177 RAMATHAL 40 F 1219/07 B, T R. BUCCAL VC  T4N1M0 CT + RT  Defau 
178 VELLAISWAMY 30 F 1221/07 B L. BUCCAL SCC I T3N2M0 CT  Progr 
179 INDIRANI 41 F 1232/07 B, T L. BUCCAL SCC II T3N0M0 CT + RT  Asymp 
180 NANJA GOUNDER 71 M 1253/07 B, S, T L. BUCCAL SCC I T2N2M0 CT  Defau 
181 PARAMASIVAM 60 M 1274/07 S, A TONGUE SCC I T2N1M0 CT + RT  Asymp 
182 BABY 31 F 1276/07 B, T L. BUCCAL SCC I T4N1M0 CT  Defau 
183 DHANALAKSHMI 48 F 1300/07 B, T R. BUCCAL SCC II T4N0M0 CT + RT  Asymp 
184 VEERAN 70 M 1325/07 S, A, T R. BUCCAL SCC I T3N2M0 CT  Progr 
185 TIRUSELVAM 41 M 1353/07 S, A FOM SCC II T2N0M0 CT + RT  Asymp 
186 NALLAMMAL 70 F 1373/07 B, T R. BUCCAL SCC I T4N1M0 CT + RT  Defau 
187 RAMASWAMY 44 M 1378/07 B, S, T R. BUCCAL SCC II T3N1M0 2 CT+SY+ RT WE, HM, FF Asymp 
188 RAJAMMAL 40 F 1388/07  TONGUE SCC I T2N2M0 CT  Progr 
189 KANNAMMAL 55 F 1406/07 B, T R. BUCCAL SCC II T4N1M0 CT + RT  Asymp 
190 CHENNIYAMMAL 60 F 1407/07 B L. BUCCAL SCC I T3N0M0 CT  Asymp 
191 SADASIVAM 56 M 1415/07 S, A L.BUCCAL SCC II T2N2M0 CT  Defau 
192 PALANISWAMY 65 M 1430/07 S, T FOM SCC I T4N0M0 CT + RT  Asymp 
193 THANGAVEL 57 M 1437/07 B, S HARD PAL SCC II T4N1M0 CT  Defau 
194 KANNAMMAL 58 F 1439/07 B ALVEOLUS SCC I T2N0M0 CT + RT  Asymp 
195 KANNAMMAL 45 F 1482/07  HARD PAL SCC II T3N2M0 CT  Defau 
196 SANKUNTHALA 45 F 1529/07 B, T R. BUCCAL SCC I T2N1M0 CT + RT  Asymp 
197 SARESHATTY 48 F 1536/07 B, T L. BUCCAL SCC II T4N1M0 CT  Defau 
198 SEKHAR 45 F 1541/07  TONGUE SCC I T2N2M0 CT  Defau 
199 KUPPUSAMY 70 M 1552/07 B, S, T HARD PAL SCC I T3N1M0 CT  Asymp 
200 RUCKMANI 60 F 1584/07 B, T TONGUE SCC I T3N0M0 SY + CT + RT  HG, TF Asymp 
201 KAMALA 65 F 1600/07 B, T L. BUCCAL SCC I T3N1M0 CT  Asymp 
202 LOGANATHAN 52 M 1606/07 S, A, T TONGUE SCC I T4N1M0 CT + RT  Defau 
203 KAMACHI 53 F 1610/07 B, T R. BUCCAL SCC II T2N1M0 CT  Asymp 
204 ARUMUGAM 63 M 1617/07 S, A TONGUE SCC I T3N2M0 CT + RT  Progr 
205 ANNAPOORANI 55 F 1619/07 B, T R. BUCCAL SCC I T3N1M0 CT  Asymp 
206 KRISHNAMURTHY 62 M 1622/07 S, A ALVEOLUS SCC II T4N0M0 CT + RT  Asymp 
207 RENGAMMAL 60 F 1645/07  TONGUE SCC I T3N2M0 CT  Defau 
208 PONNI 62 F 1653/07 B, T L. BUCCAL SCC II T4N1M0 CT + RT  Defau 
209 MEENACHI 74 F 1659/07 B, T ALVEOLUS SCC I T3N0M0 CT  Asymp 
210 VASANTHI 54 F 1672/07 B, T L. BUCCAL SCC II T3N2M0 CT + RT  Progr 
211 PONNURAJ 65 M 1679/07 S, A, T TONGUE SCC I T4N1M0 CT  Defau 
212 JALEEL 54 M 1684/07 S, A, T TONGUE SCC I T2N1M0 SY + CT + RT HG, MRND Asymp 
213 DEIVANAI 80 F 1/08 B L. BUCCAL SCC II T2N2M0 CT + RT  Progr 
214 RAMASWAMY 70 M 19/08 S, A, T LIP VC  T4N0M0 SY + CT WE, AF Asymp 
215 PERIYATHAL 65 F 20/08 B, T L. BUCCAL SCC II T3N1M0 CT  Defau 
216 RAJAMMAL 55 F 22/08 B, T R. BUCCAL SCC I T2N2M0 CT + RT  Progr 
217 CHELLAMMAL 69 F 45/08 B, T L. BUCCAL SCC II T2N1M0 CT  Asymp 
218 RENGAMMAL 60 F 54/08 B, T TONGUE SCC I T3N2M0 CT + RT  Progr 
219 SARASA 55 F 84/08 B R. BUCCAL SCC I T4N1M0 CT + RT  Defau 
220 ANDAL 65 F 94/08 B, T L. BUCCAL SCC I T3N0M0 CT  Asymp 
221 MANICKAM 52 M 100/08 S TONGUE SCC II T3N1M0 CT + RT  Defau 
222 PERUMAL 69 M 141/08 S, A FOM SCC I T2N0M0 CT  Asymp 
223 CHANALAKSHMI 65 F 157/08 B TONGUE SCC II T3N2M0 CT + RT  Progr 
224 MARASWAMY 60 M 165/08 S, A, T HARD PAL SCC I T2N0M0 CT  Asymp 
225 NACHIMUTHU 65 M 169/08 S, A TONGUE SCC I T4N1M0 CT + RT  Defau 
226 PADMAVATHY 57 F 173/08 B, T R. BUCCAL SCC II T4N0M0 CT  Asymp 
227 KALIMUTHU 67 M 181/08 S R. BUCCAL SCC I T4N1M0 CT + RT  Defau 
228 CHELLAMUTHU 57 M 186/08 B, A TONGUE SCC II T2N1M0 CT + RT  Asymp 
229 PAVAMMAL 75 F 200/08 B, T L. BUCCAL SCC I T4N1M0 CT + RT  Defau 
230 ARUNTHATHY 57 F 202/08  HARD PAL SCC I T3N0M0 CT  Asymp 
231 PONNUTHAI 65 F 217/08  TONGUE SCC I T3N2M0 CT + RT  Defau 
232 KANNAMMAL 60 F 136/08 B, T L. BUCCAL SCC II T3N1M0 CT + RT  Defau 
233 NAGARAJ 40 F 240/08 B L. BUCCAL SCC I T4N1M0 CT + RT  Defau 
234 NAVAKODI 54 M 245/08 B, S, T TONGUE SCC I T3N0M0 CT  Asymp 
235 NATARAJ 60 M 259/08 B, S TONGUE SCC I T4N0M0 CT + RT  Asymp 
236 PALANIAMMAL 60 F 264/08 B, T L. BUCCAL SCC I T4N1M0 CT  Asymp 
237 MARATHAL 75 F 281/08 B, T ALVEOLUS SCC I T2N0M0 CT  Asymp 
238 VELAYUTHAM 67 F 287/08 B, T TONGUE SCC I T3N2M0 CT + RT  Progr 
239 PALANISWAMY 60 M 313/08 S, A, T TONGUE SCC I T4N1M0 CT + RT  Progr 
240 KARUPPAMMAL 50 F 344/08 B TONGUE SCC II T4N1M0 CT + RT  Defau 
241 THANAVEL 70 M 345/08 S, A, T TONGUE SCC I T4N0M0 CT + RT  Asymp 
242 LAKSHMI 80 F 349/08 B, T R. BUCCAL SCC II T3N0M0 CT  Asymp 
243 PETCHIAMMAL 56 F 369/08  HARD PAL SCC I T4N1M0 CT + RT  Defau 
244 FATHIMA 52 F 371/08 B, T L. BUCCAL SCC I T3N2M0 CT + RT  Progr 
245 GANAGARAJ 62 F 374/08 B, T TONGUE SCC I T2N1M0 CT  Defau 
246 RANJITHAM 67 F 389/08 B, T TONGUE SCC I T4N1M0 CT + RT  Asymp 
247 PALANI 50 M 392/08 S, A, T TONGUE SCC I T3N1M0 CT  Defau 
248 MATHAN 55 M 425/08 B, S, T L. BUCCAL SCC I T3N2M0 CT + RT  Progr 
249 RAYAN 54 M 430/08 S, A TONGUE SCC I T4N1M0 CT + RT  Defau 
250 THANGAVEL 55 M 443/08 S TONGUE SCC II T4N1M0 CT  Defau 
251 NACHIAMMAL 50 F 445/08 B, T LIP SCC I T3N2M0 CT + RT  Defau 
252 LINGAMMAL 80 F 446/08 B, T TONGUE SCC II T4N0M0 CT  Asymp 
253 RAYANAN 35 M 458/08 S TONGUE SCC I T3N0M0 CT + RT  Asymp 
254 RENGASWAMY 72 M 472/08 B,S,A,T ALVEOLUS SCC I T2N1M0 CT  Defau 
255 DURAIRAJ 54 M 473/08 S HARD PAL SCC II T2N0M0 CT + RT  Asymp 
256 KAVERI 57 F 480/08 B, T R. BUCCAL SCC I T3N2M0 CT + RT  Progr 
257 RENGAMMAL 52 F 484/08 B TONGUE SCC I T4N1M0 CT  Defau 
258 RENGRAJ 65 M 509/08 S, A, T FOM SCC II T3N1M0 CT + RT  Asymp 
259 VALLIAMMAL 80 F 527/08 B LIP SCC I T3N0M0 SY + CT WE, MF Asymp 
260 MURUGAN 55 M 530/08 B, A TONGUE SCC I T4N1M0 CT + RT  Defau 
261 PALANISWAMY 50 M 533/08 S TONGUE SCC I T3N1M0 CT  Progr 
262 RAJA 36 M 534/08 B,S,A,T TONGUE SCC II T4N1M0 CT + RT  Defau 
263 KAMACHI 80 F 556/08 B LIP SCC I T4N0M0 CT  Asymp 
264 KARUPATHAL 65 F 567/08 B ALVEOLUS SCC I T2N0M0 CT + RT  Asymp 
265 PENYAL 78 F 576/08 B L. BUCCAL SCC I T4N1M0 CT  Defau 
266 MARIVEL 45 M 583/08 S, A, T TONGUE SCC I T3N1M0 CT + RT  Asymp 
267 VELLINGIRI 70 F 607/08 B TONGUE SCC I T3N1M0 CT  Defau 
268 AJAMATHULLA 52 M 612/08 S, A, T ALVEOLUS SCC II T2N1M0 SY + CT + RT WE, STM Asymp 
269 DEVAKI 70 F 618/08 B R. BUCCAL SCC I T3N0M0 CT  Asymp 
270 PARVATHI 70 F 637/08 B, T L. BUCCAL VC  T1N0M0 SY WE, TF Rec, ct 
271 RAJAPPAN 50 M 645/08 B, T L. BUCCAL SCC I T4N0M0 CT  Defau 
272 PAPATHY 48 F 652/08 B R. BUCCAL SCC II T4N1M0 RT + SY +CT WE,HM,DPF Asymp 
273 PITCHAIMUTHU 68 M 682/08 B,A, T R. BUCCAL SCC I T3N2M0 CT + RT  Progr 
274 RUKUMANI 68 F 692/08  TONGUE SCC II T2N0M0 CT  Asymp 
275 YESUDAS 65 M 709/08 S, T TONGUE SCC I T4N1M0 CT  Asymp 
276 CHINNAMMAL 50 F 743/08 B, T L. BUCCAL SCC I T3N1M0 CT + RT  Asymp 
277 SHUNMUGAM 62 M 749/08 S, T R. BUCCAL SCC I T3N0M0 CT  Defau 
278 PALANISWAMY 57 M 763/08 S, A, T TONGUE SCC II T2N2M0 CT + RT  Asymp 
279 PALANISWAMY 45 M 768/08 S L. BUCCAL SCC I T4N1M0 CT  Defau 
280 AMUTHA 60 F 778/08 B R. BUCCAL SCC I T4N2M0 CT + RT  Progr 
281 PAPATHY 60 F 781/08 B R. BUCCAL SCC II T3N2M0 CT + RT  Defau 
282 BEGAM 60 F 786/08 B R. BUCCAL SCC I T2N1M0 CT  Asymp 
283 PALANISWAMY  45 M 787/08 S TONGUE SCC I T2N2M0 CT + RT  Progr 
284 MOHAMEDHABERLLA 40 M 792/08 B, T R. BUCCAL SCC I T4N1M0 CT  Asymp 
285 RENGAL 45 F 793/08 B, T L. BUCCAL SCC III T2N2M0 CT + RT  No resp 
286 THANGAVEL 57 M 846/08 S, A, T ALVEOLUS SCC I T2N0M0 SY + CT HM, DPF Defau 
287 RAMAL 50 F 849/08 B LIP SCC II T3N2M0 CT + RT  Defau 
288 NACHAMMAL 60 F 852/08 B R. BUCCAL SCC I T4N0M0 CT  Asymp 
289 KONDAPPAN 62 M 864/08 S, T TONGUE SCC II T3N1M0 CT  Defau 
290 SAROJINI 48 F 866/08 B R. BUCCAL SCC I T4N1M0 CT  Defau 
291 MALATHY 45 F 867/08 B L. BUCCAL SCC II T3N0M0 CT  Asymp 
292 THERASAMMAL 70 F 870/08 B ALVEOLUS SCC I T3N2M0 CT + RT  Progr 
293 CHELLAMMAL 45 F 875/08 B L. BUCCAL SCC II T3N0M0 CT  Asymp 
294 SARASU 50 F 888/08 B ALVEOLUS SCC I T2N2M0 CT + RT  Defau 
295 ISMAIL 46 M 906/08 B, S, T L. BUCCAL VC  T4N1M0 CT  Defau 
296 RAMAIH 60 M 947/08 B, S, T L. BUCCAL SCC I T3N1M0 CT  Asymp 
297 IYYASWAMY 60 M 953/08 S, T FOM SCC II T3N2M0 CT + RT  Defau 
298 NAGAMMAL 45 F 958/08  L. BUCCAL SCC I T2N1M0 CT  Asymp 
299 ANANTH 38 M 988/08 S, A, T LIP SCC II T4N1M0 CT  Defau 
300 SELVI 43 F 1020/08 B, T L. BUCCAL SCC I T3N1M0 CT  Asymp 
301 UDAYAKUMAR 48 M 1029/08 S, T TONGUE SCC II T2N2M0 CT + RT  Progr 
302 DANDAPANI 52 M 1033/08 S, A, T FOM SCC I T2N0M0 CT  Asymp 
303 DHANARAJ 47 M 1038/08 S, A, T ALVEOLUS VC  T4N1M0 CT  Defau 
304 RAMATHAL 60 F 1045/08 B, T TONGUE SCC I T4N0M0 CT  Asymp 
305 PALANIVEL 45 M 1053/08 B, S, T R. BUCCAL SCC I T3N0M0 CT  Asymp 
306 THIRUMATHAL 45 F 1057/08 B R. BUCCAL SCC I T4N0M0 CT  Asymp 
307 GOVINDARAJ 59 M 1060/08 S, A, T R. BUCCAL SCC I T4N1M0 CT + RT  Progr 
308 POOVATHAL 75 F 1076/08 B ALVEOLUS SCC I T4N0M0 CT + RT  Asymp 
309 SAKALIAMMAL 70 F 1093/08  TONGUE SCC I T2N0M0 SY WE, PC Defau 
310 KUNCHAMMAL 66 F 1096/08 B L. BUCCAL SCC I T3N1M0 CT + RT  Defau 
311 MANICHANDRA 80 F 1107/08 B R. BUCCAL SCC II T3N2M0 CT + RT  Progr 
312 KARUPPASWAY 70 M 1110/08 B,S,A,T L. BUCCAL SCC I T4N1M0 CT  Defau 
313 KASIM 65 M 1136/08 S, A, T LIP SCC I T1N1M0 CT + RT  Asymp 
314 MALAIYAL 65 F 1139/08 B L. BUCCAL SCC I T3N2M0 CT  Defau 
315 KUPPAMMAL 45 F 1147/08  R. BUCCAL SCC II T3N1M0 CT + RT  Asymp 
316 LAKSHMI 40 F 1153/08 B TONGUE SCC I T4N1M0 CT + RT  Defau 
317 NACHIMUTHU 37 M 1166/08 S, A, T TONGUE SCC II T4N0M0 CT  Asymp 
318 NANCHI 70 F 1172/08 B, T ALVEOLUS SCC I T2N1M0 CT + RT  Defau 
319 SELVARAJ 50 M 1186/08 S,A,  T TONGUE SCC I T3N2M0 CT  Progr 
320 SUBRAMANI 60 M 1210/08 S, A TONGUE SCC I T1N1M0 CT + RT  Defau 
321 PALANIAMMAL 65 F 1211/08 B L. BUCCAL SCC II T3N2M0 CT  Progr 
322 RENGAN 75 M 1215/08 B, S R. BUCCAL SCC I T4N1M0 CT + RT  Defau 
323 THULSIMANI 65 F 1223/08 B L. BUCCAL SCC II T4N0M0 CT  Asymp 
324 PALANISWAMY 66 M 1226/08 S, A L. BUCCAL SCC I T4N1M0 CT + RT  Defau 
325 RAJENDRAN 54 M 1233/08 B, A R. BUCCAL SCC I T3N1M0 CT  Asymp 
HM – Hemimandibulectomy 
HG  - Hemiglossectomy 
WE – Wide Excision 
SM – Segmental Mandibulectomy 
DPF – Deltopectoralflap 
STM – Subtotal Maxillectomy 
TF – Tongue Flap  
MF – Modified Flap 
AF – Abbes Flap 
RND – Radical Neck Dissection 
MRND – Modified Radical Neck Dissection 
SOD – Supra Omohyoid Dissection 
FF – Forehead Flap 
NLFC – Nasolabial Flap Cover 
PC – Primary Closure 
 
 
